Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads
Related Experiment Video
Updated: Jun 4, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
S Vadivelan1, T N Deeksha, S Arun
1Informatics, GVK Biosciences Private Limited, 37 Sterling Road, Chennai 600034, Tamil Nadu, India. vadivelan@gvkbio.com
Abstract:
The purpose of this study is to identify novel and potent inhibitors against HIV-1 reverse transcriptase (RT). The crystal structure of the most active ligand was converted into a feature-shaped query. This query was used to align molecules to generate statistically valid 3D-QSAR (r(2) = 0.873) and Pharmacophore models (HypoGen). The best HypoGen model consists of three Pharmacophore features (one hydrogen bond acceptor, one hydrophobic aliphatic and one ring aromatic) and further validated using known RT inhibitors. The designed novel inhibitors are further subjected to docking studies to reduce the number of false positives. We have identified and proposed some novel and potential lead molecules as reverse transcriptase inhibitors using analog and structure based studies.
Related Concept Videos
Drug Discovery: Overview
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

